Cancers 2010, 2(1), 1-19; doi:10.3390/cancers2010001
Review

Novel Combinations for the Treatment of Metastatic Breast Cancer

Weill Cornell Medical College, 425 East 61st Street, 8th Floor, New York, NY 10065, USA
Received: 17 November 2009; in revised form: 29 December 2009 / Accepted: 5 January 2010 / Published: 14 January 2010
(This article belongs to the Special Issue Breast Cancer)
PDF Full-text Download PDF Full-Text [526 KB, uploaded 14 January 2010 13:21 CET]
Abstract: Anthracyclines and taxanes represent the mainstay of first-line cytotoxic therapy for metastatic breast cancer (MBC), but most patients eventually develop resistance to these agents. Consequently, alternative combinations for MBC therapy are the subject of much ongoing research. Capecitabine and ixabepilone is the only chemotherapy combination specifically approved for MBC after failure of anthracyclines and taxanes. Other options have limited data to support their use in this setting but are commonly used in practice. Future MBC therapies will likely combine alternative chemotherapies and novel biologic agents, and numerous ongoing trials should help to further define the proper use of these regimens.
Keywords: metastatic breast cancer; anthracycline failure; taxane failure; combination therapy; chemotherapy; targeted or biologic therapy; outcomes; survival

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Vahdat, L.T. Novel Combinations for the Treatment of Metastatic Breast Cancer. Cancers 2010, 2, 1-19.

AMA Style

Vahdat LT. Novel Combinations for the Treatment of Metastatic Breast Cancer. Cancers. 2010; 2(1):1-19.

Chicago/Turabian Style

Vahdat, Linda T. 2010. "Novel Combinations for the Treatment of Metastatic Breast Cancer." Cancers 2, no. 1: 1-19.

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert